The national board of Science for Life Laboratory

Minutes from board meeting no 31
2018-10-02 (Solna)

Present members: Carl-Henrik Heldin (chair), Karin Dahlman-Wright (KI), Fredrik Elinder (LiU), Anders Karlhede (SU), Margareta Olsson Birgersson (industry representative), Stellan Sandler (UU), Marianne Sommarin (UmU)(from § 6), Gunilla Westergren-Thorsson (LU)(from § 8)

Absent members: Sophia Hober (KTH)

Other participants: Olli Kallioniemi (Director), Siv Andersson (Co-Director), Annika Jenmalm Jensen (Infrastructure Director), Fredrik Sterky (head of operations), Jenny Alfredsson (vice head of operations), Anna Höglund Rehn (secretary)

Appendix:
A. Technology Development Project (TDP) funding
B. Funding of Pilot Facility Technologies

1. Meeting formalities
Carl-Henrik Heldin opened the meeting.

Decisions:
- The SciLifeLab board approved the minutes from meetings no 30.
- The SciLifeLab board appointed Stellan Sandler to approve the minutes in addition to the chair.

2. Update from the Director
Olli Kallioniemi presented an update about SciLifeLab and current work within the management group (MG) and operations office (OO).

3. Technology Development Project (TDP) funding
Annika Jenmalm Jensen informed the board about the call for Technology Development Projects where 51 applications were submitted. TDPs are funded as a joint initiative between national funding and SFO funding from the host universities and is intended to support 2-year research projects during 2019–2020.

The SciLifeLab management group has ranked the applications and suggested funding for 16 applications. This ranking was approved by all the host universities.

Decisions:
- The SciLifeLab board approved the top-ranked 16 proposals as SciLifeLab TDPs in 2019-2020 according to appendix A.
- The SciLifeLab board approved the use of national funding: 7008 kSEK for 2019 and 7002 kSEK for 2020.
- The use of national funding is expected to be combined with SFO-funding from the four host universities with 3000 kSEK per year per university.
- The TDP proposal from a non-host university, “Production of proteins and glycoproteins in mammalian cells”, will receive exclusively national funding.

Olli Kallioniemi and Annika Jenmalm Jensen were not present during the decision due to conflicts of interest.

4. **Midterm checkup of national facilities**
Annika Jenmalm Jensen informed the board about the midterm checkup of the national facilities. The purpose of the midterm checkup is to ensure that the infrastructure units are operating in accordance to conditions, expectations and suggestions from SciLifeLab management. In addition, well-motivated add on funding could be applied for. The SciLifeLab management have evaluated the Facility mid-term reports and will come back with facility specific feed-back and conditions for 2019 and 2020 funding.

5. **Incorporation of old Pilot Facility Projects (first phase)**
As part of the midterm checkup of the SciLifeLab infrastructure, facilities could apply for additional funding 2019-2020 for incorporation of Pilot Project Technologies arising from the previously SFO-funded Pilot Facility Projects 2016-2017/18 in Stockholm and Uppsala.

Annika Jenmalm Jensen informed the board about the 5 submitted applications which were reviewed and ranked by the SciLifeLab management group.

**Decision:**
- The SciLifeLab board approved funding for incorporation of two Pilot Facility Technologies according to appendix B.

6. **Tentative 2019 budget to national facilities and other budget items**
Olli Kallioniemi and Fredrik Sterky informed the board about the preliminary budget for the infrastructure and for the management group and operations office. The complete budget for 2019 will be approved at the next board meeting.

**Decision:**
- The SciLifeLab board was in favor of the budget proposal but postponed the budget decision to resolve a few remaining questions. The board will take a decision regarding the complete infrastructure budget per capsulam.

7. **Meeting dates 2019 and mandate periods for board members**
Carl-Henrik Heldin confirmed that a board meeting will be held February 8, 2019. A questionnaire regarding dates for the following board meetings 2019 will be sent out.
Carl-Henrik Heldin gave an update regarding the process for appointing members to the board as the mandate period for most members ends March 31, 2019.

8. **Drug Discovery and Development platform (DDD): legal representation via Uppsala University ("kanslifunktion")**
Olli Kallioniemi and Annika Jenmalm Jensen informed about the agreement for legal representation that had been delegated to the DDD management and Uppsala University to draft. All involved universities have given feedback on the draft.

A comment from the board is that it is important with a clarification regarding point 6 (Mandate), i.e. to frame the limits of the proxy.

**Decisions:**
- The SciLifeLab board supported the draft document for the establishment of a DDD office (Överenskommelse om kanslifunktion).
- The SciLifeLab board gave the directorship for SciLifeLab the mandate to negotiate the final formulations in the document with the aim to have all DDD host universities and the SciLifeLab board to approve it.

9. **Approval of members in the DDD platform steering group**
Annika Jenmalm Jensen informed about the DDD platform steering group and suggested members in the group.

**Decision:**
- The SciLifeLab board approved the members in the DDD platform steering group (mandate period until December 31, 2020):
  **Academic:**
  Håkan Billig (Göteborg University, chair)
  Maria Jenmalm (Linköping University)
  Mef Nilbert (Lund University/University of Copenhagen)
  Vacant
  **Industry/Innovation organization/funding agencies:**
  Kjell Sackariassen (Kellsa)
  Anna Sandström (AstraZeneca)
  Charlotte Edenius (ALS, Allmora Life Science AB)

10. **Planning the visit of the International Advisory Board (IAB) on March 13-15, 2019**
Olli Kallioniemi informed the board about the program for the upcoming visit by IAB and the outlines for the IAB report.

Two new members need to be appointed to the IAB committee and the board discussed possible candidates.

**Decision:**
- The SciLifeLab board gave the chair and the directorship mandate to
approach candidates. The aim is to appoint the new members at the next board meeting.

11. First National SciLifeLab Committee (NSC) meeting
Siv Andersson gave an update from the first meeting with the National SciLifeLab Committee September 5, 2018. The next NSC meeting will take place November 5, 2018.

The committee’s primarily tasks are to
- give advice to guide SciLifeLab management,
- give advice to ensure national impact on the infrastructure,
- be contact points and ambassadors for SciLifeLab at each university,
- support and advice with new national calls, programs and initiatives,
- support other national initiatives.

12. Follow-up on board strategy meeting
Olli Kallioniemi gave his reflections regarding earlier strategy discussions in the board, the management group and the National SciLifeLab committee.

13. Other issues
No other issues.

Upcoming meetings:

November 15, 2018 at 10.00-15.00 in Stockholm (Earth, Gamma 2)
February 8, 2019 at 10.00-15.00 in Stockholm (Earth, Gamma 2)

Anna Höglund Rehn, secretary______________________________

Minutes approved by:

Carl-Henrik Heldin_____________________________________

Stellan Sandler_________________________________________
# Appendix A. Technology Development Project (TDP) funding

<table>
<thead>
<tr>
<th>Project Title</th>
<th>Last name</th>
<th>First name</th>
<th>University</th>
<th>MG member with conflict of interest</th>
<th>Applied funding 2019 (kSEK)</th>
<th>Applied funding 2019 (kSEK)</th>
<th>Proposed Funding 2019 (kSEK)</th>
<th>Proposed Funding 2020 (kSEK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-throughput screening in live zebrafish</td>
<td>Alatou</td>
<td>Amin</td>
<td>LU</td>
<td>–</td>
<td>1423</td>
<td>1430</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>BIPCD</td>
<td>Altun</td>
<td>Mikael</td>
<td>KI</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Eukaryotic protein production for biomedical research</td>
<td>Amunts</td>
<td>Alexey</td>
<td>SU</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Mass Spectrometry Imaging in Neuroscience (Neuro-MSI)</td>
<td>Andersen</td>
<td>Per</td>
<td>LU</td>
<td>–</td>
<td>2 000</td>
<td>2 000</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>MF-SIM</td>
<td>Briemar</td>
<td>Hjalmar</td>
<td>KTH</td>
<td>–</td>
<td>1 152</td>
<td>792</td>
<td>1 152</td>
<td>702</td>
</tr>
<tr>
<td>High-dimensional secretomic analysis of single cells for systems-level immuno-monitoring</td>
<td>Brodin</td>
<td>Petter</td>
<td>KI</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Production of proteins and glycoproteins in mammalian cells</td>
<td>Bäckström</td>
<td>Malin</td>
<td>GU</td>
<td>–</td>
<td>1 000</td>
<td>1 000</td>
<td>1 000</td>
<td>1 000</td>
</tr>
<tr>
<td>Ultra-sensitive monitoring of tumor DNA in plasma from cancer patients</td>
<td>Cavaller</td>
<td>Lucia</td>
<td>LU</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Novel method for identifying the effect of DNA sequence variants on common diseases</td>
<td>Johansson</td>
<td>Asa</td>
<td>LU</td>
<td>–</td>
<td>1 498</td>
<td>1 499</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Multiplexed imaging tools for high-dimensional protein maps of human cells and tissues</td>
<td>Lundberg</td>
<td>Emma</td>
<td>KTH</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Spatial Genomics</td>
<td>Lundberg</td>
<td>Joakim</td>
<td>KTH</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Deep and quantitative phosphoproteomic profiling of biological samples</td>
<td>Mundt</td>
<td>Filip</td>
<td>KI</td>
<td>Janne Lehkö</td>
<td>1 500</td>
<td>–</td>
<td>1 100</td>
<td>400</td>
</tr>
<tr>
<td>RIF-Seq: RNA isolation free RNA sequencing</td>
<td>Nilsson</td>
<td>Mats</td>
<td>SU</td>
<td>Mats Nilsson</td>
<td>1 472</td>
<td>1 418</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>CRISPR Screening 2.0</td>
<td>Schmächer</td>
<td>Bernhard</td>
<td>KI</td>
<td>–</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Improved drug discovery using single-cell resolution target-engagement profiling</td>
<td>Seashore-</td>
<td>Ludiof</td>
<td>KI</td>
<td>Olli Kallionen, Annika Jonnalm Jønsen</td>
<td>1 500</td>
<td>1 500</td>
<td>1 212</td>
<td>1 300</td>
</tr>
<tr>
<td>Artificial Intelligence and Image Analysis for Whole Slide Imaging (AIASi-WSI)</td>
<td>Wäntby</td>
<td>Carolina</td>
<td>LU</td>
<td>–</td>
<td>1 415</td>
<td>1 439</td>
<td>1 212</td>
<td>1 300</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2019 (kSEK)</th>
<th>2020 (kSEK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total:</td>
<td>19 008</td>
<td>19 002</td>
</tr>
<tr>
<td>GFO:</td>
<td>12 000</td>
<td>12 000</td>
</tr>
<tr>
<td>National:</td>
<td>7 008</td>
<td>7 002</td>
</tr>
</tbody>
</table>
## Appendix B: Funding of Pilot Facility Technologies

<table>
<thead>
<tr>
<th>No.</th>
<th>Platform</th>
<th>Applying Facility</th>
<th>Pilot Technology</th>
<th>MG member with conflict of interest</th>
<th>Funding applied for 2019 (kSEK)</th>
<th>Funding applied for 2020 (kSEK)</th>
<th>Proposed funding 2019 (kSEK)</th>
<th>Proposed funding 2020 (kSEK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cellular and Molecular Imaging</td>
<td>Advanced Light Microscopy (ALM)</td>
<td>Next Generation Selective Plane Illumination Microscopy for High-Resolution Tissue Imaging</td>
<td>–</td>
<td>589</td>
<td>589</td>
<td>500</td>
<td>300</td>
</tr>
<tr>
<td>2</td>
<td>Cellular and Molecular Imaging</td>
<td>Cryo-EM</td>
<td>Computational Service at the Existing Cryo-EM Facility</td>
<td>–</td>
<td>1 420</td>
<td>1 420</td>
<td>1 000</td>
<td>800</td>
</tr>
</tbody>
</table>